Europe CBD Products Market Research Report Forecast to 2028

Description

List of Tables

The Europe CBD products market has witnessed substantial growth over the last few years and is projected to reach USD 880.56 million by the end of 2028, registering a CAGR of 9.74% during the forecast period, 2021-2028. Few significant reasons for the growth of the Europe CBD products market are growing incidences of chronic diseases and related health issues among consumers, followed by the gradual legalization of cannabinoid (CBD) across Europe. Moreover, megatrends and technological advancements in the production process and increasing R&D on cannabinoids have provided the market players an opportunity to flourish in the Europe CBD products market. However, adverse health effects associated with the consumption of cannabis are expected to hinder market growth in the next few years.

The Europe CBD products market is expected to record a CAGR of 9.74% during the forecast period. The rising prevalence of chronic diseases and related complications are the key factors driving the growth of the Europe CBD products market. The legalization of cannabinoid (CBD) in Europe is another factor contributing to the growth of the CBD products market. Moreover, megatrends and technological advancements and increasing R&D in cannabinoid Ayurveda are likely to create an opportunistic market for the players to grow and expand. However, adverse effects associated with cannabis among CBD products manufacturers create a challenging situation for the players in the Europe CBD products market.

Market Segmentation

Based on type, the Europe CBD products market has been segmented into CBD oil, CBD buds, and others. The CBD oil segment accounted for the largest market share of 81.17% in 2020.

Based on application, the Europe CBD products market has been segmented into cosmetics and medical purpose. The medical purpose segment accounted for a larger market share of 73.25% in 2020.

Regional Analysis

Europe CBD products market has been segmented, based on country, into UK, Germany, France, Spain, Italy, Switzerland, Austria, Poland, and the Rest of Europe.

Germany accounted for the largest market share of 25.07% in 2020, with a market value of USD 105.19 million; the market is expected to register a CAGR of 9.90%. The UK was the second-largest market in 2020, valued at USD 97.68 million; the market is projected to exhibit a CAGR of 9.49%. However, the market in Rest of Europe is expected to register the highest CAGR of 10.65% during the forecast period.

Major Players

The key players operating in the Europe CBD products market include CV Sciences, Inc. (US), Hempire Gardens (Spain), Essentia Pura d.o.o. (Slovenia), Cannactiva SCP (Spain), Ilesol Pharmaceuticals d.o.o. (Republic of Croatia), Hempifarm (Netherlands), Sequoia Cannabis Ltd. (Poland), Candropharm BV (Netherlands), Grunkraft AG (Switzerland) and Widora International Srl (Italy) and the market also comprises several local players.

COVID 19 Impacts

We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries. Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.

Product Code: NA

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

1.1 MARKET ATTRACTIVENESS ANALYSIS
- 1.1.1 EUROPE CBD PRODUCTS MARKET, BY TYPE
- 1.1.2 EUROPE CBD PRODUCTS MARKET, BY APPLICATION

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 KEY BUYING CRITERIA

3 RESEARCH METHODOLOGY

3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
3.6 LIST OF ASSUMPTIONS & LIMITATIONS

4 MARKET INSIGHTS

5 MARKET DYNAMICS

5.1 INTRODUCTION
5.2 DRIVERS
- 5.2.1 RISING OCCURRENCE OF CHRONIC DISEASES AND RELATED COMPLICATIONS
- 5.2.2 LEGALIZATION OF CANNABINOID (CBD) IN EUROPE
- 5.2.3 DRIVERS IMPACT ANALYSIS
5.3 RESTRAINTS
- 5.3.1 ADVERSE EFFECTS ASSOCIATED WITH CANNABIS
- 5.3.2 RESTRAINTS IMPACT ANALYSIS
5.4 OPPORTUNITIES
- 5.4.1 MEGATRENDS AND TECHNOLOGICAL ADVANCEMENTS
- 5.4.2 INCREASING R&D ON CANNABINOID

6 MARKET FACTOR ANALYSIS

6.1 VALUE CHAIN ANALYSIS
- 6.1.1 RESEARCH & DEVELOPMENT
- 6.1.2 MANUFACTURING
- 6.1.3 DISTRIBUTION & SALES
- 6.1.4 POST-SALES MONITORING
6.2 TECHNOLOGICAL INNOVATION
- 6.2.1 CBD HEMP FARMING
- 6.2.2 EXTRACTION METHODS
- 6.2.3 EMULSION TECHNOLOGY
6.3 COMPETITORS & PRODUCT ANALYSIS
- 6.3.1 INTRODUCTION
- 6.3.2 MARKET STRATEGY ANALYSIS
- 6.3.3 PRODUCT ANALYSIS
6.4 REGULATORY SCENARIO
6.5 PORTER'S FIVE FORCES MODEL
- 6.5.1 THREAT OF NEW ENTRANTS
- 6.5.2 BARGAINING POWER OF SUPPLIERS
- 6.5.3 THREAT OF SUBSTITUTES
- 6.5.4 BARGAINING POWER OF BUYERS
- 6.5.5 INTENSITY OF RIVALRY
6.6 NEW INVESTMENT ANALYSIS
6.7 PESTEL ANALYSIS
- 6.7.1 POLITICAL FACTORS
- 6.7.2 ECONOMICAL FACTORS
- 6.7.3 SOCIAL FACTORS
- 6.7.4 TECHNOLOGICAL FACTORS
- 6.7.5 ENVIRONMENTAL FACTORS
- 6.7.6 LEGAL FACTORS
6.8 IMPACT OF THE COVID-19 OUTBREAK ON EUROPE CBD PRODUCTS MARKET
- 6.8.1 OVERVIEW
- 6.8.2 IMPACT ON CONSUMER BEHAVIOUR
- 6.8.3 IMPACT ON EUROPE
- 6.8.4 IMPACT ON PRICING
- 6.8.5 IMPACT ON THE INDUSTRY

7 EUROPE CBD PRODUCTS MARKET, BY TYPE

7.1 OVERVIEW
- 7.1.1 EUROPE CBD PRODUCTS MARKET ESTIMATES & FORECAST, BY TYPE, 2016-2028
7.2 CBD OIL
- 7.2.1 CBD OIL: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2016-2028
7.3 CBD BUDS
- 7.3.1 CBD BUDS: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2016-2028
7.4 OTHERS
- 7.4.1 OTHERS: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2016-2028

8 EUROPE CBD PRODUCTS MARKET, BY APPLICATION

8.1 OVERVIEW
- 8.1.1 EUROPE CBD PRODUCTS MARKET ESTIMATES & FORECAST, BY APPLICATION, 2016-2028
8.2 COSMETICS
- 8.2.1 COSMETICS: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2016-2028
8.3 MEDICAL PURPOSE
- 8.3.1 MEDICAL PURPOSE: MARKET ESTIMATES & FORECAST, BY COUNTRY, 2016-2028

9 EUROPE CBD PRODUCTS MARKET, BY COUNTRY

9.1 OVERVIEW
9.2 UK
9.3 GERMANY
9.4 FRANCE
9.5 SPAIN
9.6 ITALY
9.7 SWITZERLAND
9.8 AUSTRIA
9.9 POLAND
9.10 REST OF EUROPE

10 COMPANY PROFILES

10.1 CV SCIENCES, INC.
- 10.1.1 COMPANY OVERVIEW
- 10.1.2 FINANCIAL OVERVIEW
- 10.1.3 PRODUCTS OFFERED
- 10.1.4 SWOT ANALYSIS
10.2 HEMPIRE GARDENS
- 10.2.1 COMPANY OVERVIEW
- 10.2.2 FINANCIAL OVERVIEW
- 10.2.3 PRODUCTS OFFERED
- 10.2.4 SWOT ANALYSIS
10.3 ESSENTIA PURA D.O.O.
- 10.3.1 COMPANY OVERVIEW
- 10.3.2 FINANCIAL OVERVIEW
- 10.3.3 PRODUCTS OFFERED
- 10.3.4 SWOT ANALYSIS
10.4 CANNACTIVA SCP
- 10.4.1 COMPANY OVERVIEW
- 10.4.2 FINANCIAL OVERVIEW
- 10.4.3 PRODUCTS OFFERED
- 10.4.4 SWOT ANALYSIS
10.5 ILESOL PHARMACEUTICALS D.O.O.
- 10.5.1 COMPANY OVERVIEW
- 10.5.2 FINANCIAL OVERVIEW
- 10.5.3 PRODUCTS OFFERED
- 10.5.4 SWOT ANALYSIS
10.6 HEMPIFARM
- 10.6.1 COMPANY OVERVIEW
- 10.6.2 FINANCIAL OVERVIEW
- 10.6.3 PRODUCTS OFFERED
- 10.6.4 SWOT ANALYSIS
10.7 SEQUOIA CANNABIS LTD.
- 10.7.1 COMPANY OVERVIEW
- 10.7.2 FINANCIAL OVERVIEW
- 10.7.3 PRODUCTS OFFERED
- 10.7.4 SWOT ANALYSIS
10.8 CANDROPHARM BV
- 10.8.1 COMPANY OVERVIEW
- 10.8.2 FINANCIAL OVERVIEW
- 10.8.3 PRODUCTS OFFERED
- 10.8.4 SWOT ANALYSIS
10.9 GRUNKRAFT AG
- 10.9.1 COMPANY OVERVIEW
- 10.9.2 FINANCIAL OVERVIEW
- 10.9.3 PRODUCTS OFFERED
- 10.9.4 SWOT ANALYSIS
10.10 WIDORA INTERNATIONAL SRL
- 10.10.1 COMPANY OVERVIEW
- 10.10.2 FINANCIAL OVERVIEW
- 10.10.3 PRODUCTS OFFERED
- 10.10.4 SWOT ANALYSIS

11 REFERENCES